A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 853 in Adolescent (greater than or equal to 12 to less than 18 Years) and Adult Subjects With Intermittent or Mild to Moderate Persistent Asthma.
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2011
At a glance
- Drugs AMG-853 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Amgen
- 21 Apr 2011 Status changed from not yet recruiting to discontinued.
- 05 Aug 2010 Additional trial location [USA] identified as reported by ClinicalTrials.gov.
- 11 Jun 2010 New trial record